medigraphic.com
ISSN 1405-8871 (Print)

2017, Number 4

<< Back Next >>

Aten Fam 2017; 24 (4)

Analysis of Cardiovascular Risk Factors: Indicators of Hospital Quality in Acute Ischemic

Palazón-Cabanes B, Gómez-Jara B, Martínez-Lerma EJ, Morales-Ortiz A, Leal-Hernández M, Abellán-Alemán J

Language: Spanish
References: 28
Page: 150-155
PDF size: 228.97 Kb.


ABSTRACT

Objective: to analyze and know the prevalence of (cvrf ) Cardiovascular Risk Factors and their influence in the times and in-hospital stroke code process indicators. Methods: descriptive and cross-sectional study of patients with acute ischemic ictus treated with therapies of reperfusion in a tertiary hospital (Hospital Virgen of Arrixaca, Murcia, Spain) between 2009-2016. It was analyzed the in-hospital times, quality indicators as well as the influence of the cvrf in them. Results: 376 patients were treated; high blood pressure (hbp) and age were the most significant cvrf (67.3%), followed by atrial flutter (af ) at 43.1%; there was none cvrf in 0.1%. Age and chronic alcoholism conditioned a lengthening of in-hospital time; in addition, age and diabetes were identified as negative conditioning factors of the door-neuroimaging indicator ≤25 minutes. No statistically significant differences according to sex, high blood pressure, hypercholesterolemia, fa or tobacco consumption were found. Conclusions: however the majority of patients with acute ischemic ictus pre- sented some cvrf and this fact entails a greater risk of suffering a stroke, in general, patients do not receive inhospital care in the acute phase of the ictus different from those without cvrf.


REFERENCES

  1. Masjuan J, Álvarez-Sabín J, Arenillas J, Calleja S, Castillo J, Dávalos A, et al. Plan de asistencia sanitaria al ictus ii 2010. Neurología. 2011;26(7):383- 96.

  2. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention. A systematic review. jama 2015;313(14):1451-1462

  3. Asadi H, Yan B, Dowling R, Wong S, Mitchell P. Advances in Medical Revascularisation Treatment in Acute Ischemic Stroke. Trombosis. 2014:714218.

  4. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke. Lancet Neurol. 2010;9(9):866-74.

  5. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (sits-most). Lancet. 2007;369(9558):275-82.

  6. Martí-Villalta JL. Enfermedades vasculares cerebrales. 3a ed. Barcelona: Editorial Mayo; 2012.

  7. Gomis M, Dávalos A. Recanalization and reperfusión therapies of acute ischemic stroke: what have we learned, what are the major research questions, and where are we headed? Front Neurol. 2014;19(5):226.

  8. Köhrmann M, Schellinger PD, Breuer L, Dohrn M, Kuramatsu JB, Blinzler C, et al. Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. International Journal of Stroke. 2011;6:493-7.

  9. The National Institute of Neurological Disorders and Stroke rtpa Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-7.

  10. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40:2079-84.

  11. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. jama. 2013:309(23):2480-8.

  12. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ecass, atlantis, ninds, and epithet trials. Lancet. 2010;375:1695-703.

  13. Cocho D, Belvis R, Martí-Fabregas J, Molina- Porcel L, Díaz-Manera J, Aleu A, et al. Reasons for exclusión from thrombolytic therapy after acute ischemic stroke. Neurology. 2005;64(4):719-20.

  14. Pérez de la Ossa-Herrero. El acceso precoz a centros de referencia de ictus ofrece beneficio clínico: el Código Ictus. Rev Neurol. 2008;47(8):427-33.

  15. Alvarez-Sabín J, Molina CA, Abilleira S, Montaner J, García Alfranca F, Jiménez Fabrega X, et al. Impacto del código ictus en la eficacia del tratamiento trombolítico. MedClin. 2003;120:47-51.

  16. Abilleira S, Gallofre M, Ribera A, Sánchez E, Tresserras R. Quality of In-Hospital Stroke Care According to Evidence-Based Performance Measures Results From the First Audit of Stroke, Catalonia (Spain) 2005/2006. Stroke. 2009;40:1433-8.

  17. Palazón-Cabanes B, Lopez-Picazo Ferrer JJ, Morales- Ortiz A, Tomás-García N. ¿Por qué se retrasa el tratamiento de reperfusión en pacientes con código ictus? Un análisis cualitativo. Rev Calid Asist [Internet]. 2016 Disponible en: http://dx.doi. org/10.1016/j.cali.2016.01.006

  18. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2013;44:870-947.

  19. Fonarow GC, Smith EE, Saver JL, Reeves MJ, Hernández AF, Peterson ED, et al. Improving door-toneedle times in acute ischemic stroke the design and rationale for the American Heart Association/ American Stroke Association’s target: stroke initiative. Stroke. 2011;42(10):2983-9.

  20. Mehta BP, Leslie-Mazwi TM, Chandra RV, Bell DL, Sun CHJ, Hirsch JA, et al. Reducing Door-to- Puncture Times for Intra-Arterial Stroke Therapy: A Pilot Quality Improvement Project. J Am Heart Assoc. 2014;3:e000963.

  21. Kamal N, Smith EE, Stephenson C, Choi PMC, Goyal M, et al. Visualizing Acute Stroke Data to Improve Clinical Outcomes. Stroke. 2015;46:e170-e172.

  22. Palazón-Cabanes B, Lopez-Picazo Ferrer JJ, Morales- Ortiz A, Tomás-García N. Identificación de los factores condicionantes de los tiempos e indicadores de calidad en la atención intrahospitalaria al ictus agudo. Neurología. 2016;62:157-64.

  23. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 aha/asa Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Therapy. Stroke. 2015;46(10): 3020-35.

  24. Abellán Alemán J, RuilopeUrioste LM, Leal Hernández M, Armario García P, Tiberio López G, Martell Claros N. Control de los factores de riesgo cardiovascular en pacientes con ictus atendidos en atención primaria en España. Estudio ictuscare. MedClin. 2011;136(8):329-35.

  25. Acha O, Hernandez JL, Penado S, Riancho JA. Facotres de riesgo e ictus en pacienetes de diferentes edades. RevClinEsp. 2003;203(4);189-92.

  26. Arboix A, Solá E, Castillo M, Baena M. Comparación del perfil de factores de riesgo cardiovascular entre accidentes isquémicos transitorios e infartos cerebrales. MedClin. 2003:121(8):292-4.

  27. Mikulik R, Kadlecova P, Czlonkowska A, Kobayashi A, Brozman M, Svigelj V, et al. Factors Influencing In-Hospital Delay in Treatment With Intravenous Thrombolysis. Stroke. 2012;43:1578-83.

  28. Strbian D, Michel P, Ringleb P, Numminen H, Breuer L, Bodenant M, et al. Relationship between Onset-to-door time and Door-to-Thrombolysis time. A Pooled Analysis of 10 Dedicated Stroke Centers. Stroke. 2013;44:2808-13.




2020     |     www.medigraphic.com